Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Kenya’s healthcare system is witnessing a quiet transformation with the introduction of newer therapies for managing Type 2 ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor ...

Everyone aspires to live a healthy life. The catch is that health is a moving target. It’s a challenge that changes as people ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

Semaglutide is marketed under the brand names, such as Ozempic, which is primarily prescribed for those with Type 2 diabetes, and Wegovy, which is commonly prescribed for weight loss. The drug mimics ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...